{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T04:23:10Z","timestamp":1728447790063},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"DOI":"10.1186\/s13000-024-01555-5","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:18:57Z","timestamp":1728382737000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anlotinib treatment for rapidly progressing pediatric embryonal rhabdomyosarcoma in the maxillary gingiva: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Bo","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biwei","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuicui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hairong","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingzhou","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowen","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuxiang","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiujuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixian","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gangfeng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"issue":"1","key":"1555_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0051-2","volume":"5","author":"X Skapek Stephen","year":"2019","unstructured":"Skapek Stephen X, Ferrari Andrea, Gupta Abha A, Lupo Philip J, Butler Erin S, Janet, et al. Rhabdomyosarcoma Nat Reviews Disease Primers. 2019;5(1):1.","journal-title":"Rhabdomyosarcoma Nat Reviews Disease Primers"},{"issue":"11","key":"1555_CR2","doi-asserted-by":"publisher","first-page":"e230692","DOI":"10.1136\/bcr-2019-230692","volume":"12","author":"S Nangalia Richa","year":"2019","unstructured":"Nangalia Richa S, Neha SM, Abdul, Mousumi P. Rhabdomyosarcoma involving Maxilla mimicking gingival enlargement: a diagnostic challenge. BMJ Case Rep CP. 2019;12(11):e230692.","journal-title":"BMJ Case Rep CP"},{"key":"1555_CR3","doi-asserted-by":"publisher","first-page":"109937","DOI":"10.1016\/j.ejrad.2021.109937","volume":"143","author":"A Bansal","year":"2021","unstructured":"Bansal A, Goyal S, Goyal A, Jana M. WHO classification of soft tissue tumours 2020: an update and simplified approach for radiologists. Eur J Radiol. 2021;143:109937.","journal-title":"Eur J Radiol"},{"key":"1555_CR4","doi-asserted-by":"crossref","unstructured":"Loeb D.M., Thornton K., Shokek O. Pediatric soft tissue sarcomas. Surg Clin North Am. 2008;88(3):615\u201327. vii.","DOI":"10.1016\/j.suc.2008.03.008"},{"issue":"8","key":"1555_CR5","doi-asserted-by":"publisher","first-page":"953","DOI":"10.5858\/arpa.2021-0183-RA","volume":"146","author":"DM Rong Fan","year":"2022","unstructured":"Rong Fan DM, Parham LL, Wang. An Integrative Morphologic and Molecular Approach for Diagnosis and subclassification of Rhabdomyosarcoma. Arch Pathol Lab Med. 2022;146(8):953\u20139.","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"1555_CR6","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/00000478-200608000-00005","volume":"30","author":"RA Morotti","year":"2006","unstructured":"Morotti RA, Nicol KK, Parham DM, Teot LA, Moore J, Hayes J, et al. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the children\u2019s Oncology Group experience. Am J Surg Pathol. 2006;30(8):962\u20138.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"1555_CR7","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/bjc.2017.478","volume":"118","author":"B Han","year":"2018","unstructured":"Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118(5):654\u201361.","journal-title":"Br J Cancer"},{"issue":"4","key":"1555_CR8","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.2353\/ajpath.2010.100104","volume":"177","author":"G Perot","year":"2010","unstructured":"Perot G, Chibon F, Montero A, Lagarde P, de The H, Terrier P, et al. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol. 2010;177(4):2080\u201390.","journal-title":"Am J Pathol"},{"issue":"22","key":"1555_CR9","first-page":"6324","volume":"49","author":"MR Stratton","year":"1989","unstructured":"Stratton MR, Fisher C, Gusterson BA, Cooper CS. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 1989;49(22):6324\u20137.","journal-title":"Cancer Res"},{"issue":"6","key":"1555_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/ng.2969","volume":"46","author":"S Kohsaka","year":"2014","unstructured":"Kohsaka S, Shukla N, Ameur N, Ito T, Ng CK, Wang L, et al. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet. 2014;46(6):595\u2013600.","journal-title":"Nat Genet"},{"issue":"19","key":"1555_CR11","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1158\/1078-0432.CCR-20-1246","volume":"26","author":"HW Lee","year":"2020","unstructured":"Lee HW, Sa JK, Gualberto A, Scholz C, Sung HH, Jeong BC, et al. A phase II trial of Tipifarnib for patients with previously treated, metastatic urothelial carcinoma harboring HRAS mutations. Clin Cancer Res. 2020;26(19):5113\u20139.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1555_CR12","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1200\/JCO.20.02903","volume":"39","author":"AL Ho","year":"2021","unstructured":"Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, et al. Tipifarnib in Head and Neck squamous cell carcinoma with HRAS mutations. J Clin Oncol. 2021;39(17):1856\u201364.","journal-title":"J Clin Oncol"},{"key":"1555_CR13","doi-asserted-by":"crossref","unstructured":"Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, et al. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol. 2000;35(2):96\u2013103.","DOI":"10.1002\/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z"},{"issue":"3","key":"1555_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/gcc.10026","volume":"33","author":"JA Bridge","year":"2002","unstructured":"Bridge JA, Liu J, Qualman SJ, Suijkerbuijk R, Wenger G, Zhang J, et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer. 2002;33(3):310\u201321.","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"1555_CR15","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrc2536","volume":"8","author":"M Pollak","year":"2008","unstructured":"Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915\u201328.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1555_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/pbc.24605","volume":"61","author":"B Weigel","year":"2014","unstructured":"Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2014;61(3):452\u20136.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"1555_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/pbc.25334","volume":"62","author":"LM Wagner","year":"2015","unstructured":"Wagner LM, Fouladi M, Ahmed A, Krailo MD, Weigel B, DuBois SG, et al. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2015;62(3):440\u20134.","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"1555_CR18","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/annonc\/mdv171","volume":"26","author":"R Chugh","year":"2015","unstructured":"Chugh R, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, et al. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015;26(7):1459\u201364.","journal-title":"Ann Oncol"},{"key":"1555_CR19","doi-asserted-by":"crossref","unstructured":"Weigel SMB, Anderson JAMESR, Parham D, Teot LA, Rodeberg DA, Yock TI, Shulkin BL, Hawkins DS. Early results from Children\u2019s Oncology Group (COG) ARST08P1: pilot studies of cixutumumab or temozolomide with intensive multiagent chemotherapy for patients with metastatic rhabdomyosarcoma (RMS). J Clin Oncol, 2015. 33: p. Number 15_suppl.","DOI":"10.1200\/jco.2015.33.15_suppl.10015"},{"key":"1555_CR20","doi-asserted-by":"publisher","unstructured":"Lina Tang, Yonggang Wang, Jianjun Zhang, et al. Efficacy and safety of anlotinib in advanced soft tissue sarcoma: results from one of multi-centers in a phase IIB trial (ALTER0203). JCO. 2019;37:e22518. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.e22518.","DOI":"10.1200\/JCO.2019.37.15_suppl.e22518"},{"key":"1555_CR21","doi-asserted-by":"publisher","first-page":"11503","DOI":"10.1200\/JCO.2018.36.15_suppl.11503","volume":"36","author":"YCY Yao","year":"2018","unstructured":"Yao YCY, Wang S, Huang G, Cai Q, Shang G, Wang G, Qu G, Wu Q, Jiang Y, Song J, Chen J, Zhu X, Cai Z, Bai C, Lu Y, Yu Z. Jingnan Shen, and Jianqiang Cai, Anlotinib for metastasis soft tissue sarcoma: a randomized, double-blind, placebo-controlled and multi-centered clinical trial. JCO. 2018;36:11503\u201311503.","journal-title":"JCO"},{"key":"1555_CR22","doi-asserted-by":"publisher","first-page":"711704","DOI":"10.3389\/fphar.2022.711704","volume":"13","author":"S Lu","year":"2022","unstructured":"Lu S, Hong Y, Chen H, Wu L, Sun F, Wang J, et al. The efficacy and safety of Anlotinib in Pediatric patients with refractory or recurrent solid tumors. Front Pharmacol. 2022;13:711704.","journal-title":"Front Pharmacol"},{"key":"1555_CR23","doi-asserted-by":"publisher","unstructured":"Suying Lu, Juan Wang, Feifei Sun, et al. Phase I study of anlotinib in pediatric patients with high-risk, recurrent, or refractory sarcomas. JCO. 2023;41:e23538. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e23538.","DOI":"10.1200\/JCO.2023.41.16_suppl.e23538"},{"issue":"16","key":"1555_CR24","first-page":"3473","volume":"28","author":"G Liu Jiayong","year":"2022","unstructured":"Liu Jiayong G, Tian T, Zhichao L, Shu X, Jie B, Chujie, et al. Phase II study of TQB2450, a novel PD-L1 antibody, in combination with anlotinib in patients with locally advanced or metastatic soft tissue sarcoma. Clin Cancer Res. 2022;28(16):3473\u20139.","journal-title":"Clin Cancer Res"},{"key":"1555_CR25","doi-asserted-by":"crossref","unstructured":"Xiaogang S, Xinyu W, Jun Z, Yali X, Hao Z, Mian X et al. Next generation sequencing predicting clinical effect of immunotherapy on adult Rhabdomyosarcoma patient: a case report. Medicine, 2023. 102(21).","DOI":"10.1097\/MD.0000000000033858"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-024-01555-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-024-01555-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-024-01555-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:25:52Z","timestamp":1728383152000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-024-01555-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1555"],"URL":"https:\/\/doi.org\/10.1186\/s13000-024-01555-5","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics approval was waived. The written informed consent form was obtained from the patient\u2019s parents. All methods were performed in accordance with the ethical standards as laid down in the Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent to publish the clinical details and images were obtained from the patient\u2019s parents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CCL, HRB, SW, and QXO are employees of Nanjing Geneseeq Technology Inc. The remaining authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}